Published on 17 Mar 2024 on Simply Wall St. via Yahoo Finance
Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) market cap decline of US$89m may not have as much of an...
Key Insights
Institutions' substantial holdings in Lyell Immunopharma implies that they have significant influence over the company's share priceThe top 6 shareholders own 52% of the companyUsing data from analyst forecasts alongside ownership research, one can better assess the future performance of a company
If you want to know who really controls Lyell Immunopharma, Inc. (NASDAQ:LYEL), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the company with 52% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).